3 results
Approved WMOWill not start
The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…
Approved WMOCompleted
PrimaryTo evaluate the pharmacokinetics of two different tablet formulations of BCI-952 compared to the over-encapsulated BCI-952 product components.SecondaryTo evaluate the safety and tolerability following the administration of two different…
Approved WMORecruiting
1) To identify new predictors of ST, in particular of late and very late ST, and of drug eltuing stent thrombosis. 2) To observe clinical outcomes after an episode of ST.